Patients should never stop or adjust their medication without first consulting the prescribing clinician or trial investigator, as abrupt discontinuation may affect metabolic control and overall health outcomes
Recent Developments GLP-1 Market (2025-2026) In June 2026 , Novo Nordisk and Eli Lilly introduced GLP-1 pills for obesity, and their competition at the American Diabetes Association (ADA) Scientific Sessions
If you record a few dozen spins, youll quickly learn which setups deserve another attempt and which sequences rarely turn around
Below 95%, the impurity profile becomes concerning enough to potentially affect experimental outcomes
The upper arm: convenient but challenging for self-injection The back of the upper arm is the third FDA-approved site, and it occupies a unique position in the site rotation discussion
Mainstay treatments are renin-angiotensin-aldosterone system inhibitors, mineralocorticosteroid antagonists and -blockers, and, as mentioned earlier, SGLT-2 inhibitors, especially in people with comorbid diabetes
